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Passive Immunity Trial for Our Nation
(PassITON): study protocol for a
randomized placebo-control clinical trial
evaluating COVID-19 convalescent plasma
in hospitalized adults
Wesley H. Self1,2* , Thomas G. Stewart3, Allison P. Wheeler4, Wissam El Atrouni5, Amanda J. Bistran-Hall1,
Jonathan D. Casey6, Vince D. Cataldo7, James D. Chappell8, Claudia S. Cohn9, Jessica B. Collins1, Mark R. Denison8,
Marjolein de Wit10, Sheri L. Dixon1, Abhijit Duggal11, Terri L. Edwards1, Magali J. Fontaine12, Adit A. Ginde13,
Michelle S. Harkins14, Thelma Harrington15, Estelle S. Harris16, Daanish Hoda17, Tina S. Ipe18, Stuti J. Jaiswal19,
Nicholas J. Johnson20, Alan E. Jones21, Maryrose Laguio-Vila22, Christopher J. Lindsell3, Jason Mallada23,
Manoj J. Mammen24, Ryan A. Metcalf25, Elizabeth A. Middleton16, Simon Mucha11, Hollis R. O’Neal Jr26,
Sonal R. Pannu27, Jill M. Pulley1, Xian Qiao28, Jay S. Raval29, Jillian P. Rhoads1, Harry Schrager30, Carl Shanholtz15,
Nathan I. Shapiro31, Stephen J. Schrantz32, Isaac Thomsen8, Krista K. Vermillion1, Gordon R. Bernard1,6,
Todd W. Rice1,6 and For the Passive Immunity Trial for Our Nation (PassITON) Investigators

Abstract
Background: Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19).
However, the clinical efficacy of COVID-19 convalescent plasma is unclear.
Methods: The Passive Immunity Trial for Our Nation (PassITON) is a multicenter, placebo-controlled, blinded,
randomized clinical trial being conducted in the USA to provide high-quality evidence on the efficacy of COVID-19
convalescent plasma as a treatment for adults hospitalized with symptomatic disease. Adults hospitalized with
COVID-19 with respiratory symptoms for less than 14 days are eligible. Enrolled patients are randomized in a 1:1
ratio to 1 unit (200–399 mL) of COVID-19 convalescent plasma that has demonstrated neutralizing function using a
SARS-CoV-2 chimeric virus neutralization assay. Study treatments are administered in a blinded fashion and patients
are followed for 28 days. The primary outcome is clinical status 14 days after study treatment as measured on a 7(Continued on next page)
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category ordinal scale assessing mortality, respiratory support, and return to normal activities of daily living. Key
secondary outcomes include mortality and oxygen-free days. The trial is projected to enroll 1000 patients and is
designed to detect an odds ratio ≤ 0.73 for the primary outcome.
Discussion: This trial will provide the most robust data available to date on the efficacy of COVID-19 convalescent
plasma for the treatment of adults hospitalized with acute moderate to severe COVID-19. These data will be useful
to guide the treatment of COVID-19 patients in the current pandemic and for informing decisions about whether
developing a standardized infrastructure for collecting and disseminating convalescent plasma to prepare for future
viral pandemics is indicated.
Trial registration: ClinicalTrials.gov NCT04362176. Registered on 24 April 2020.
Keywords: COVID-19, SARS-CoV-2: convalescent plasma, Passive immunity, Neutralizing antibodies, Clinical trials,
Randomized controlled trial

Background
Since emerging in late 2019, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has caused a
global health crisis [1]. The disease caused by SARSCoV-2 infection, coronavirus disease 19 (COVID-19),
has caused over 2.1 million deaths worldwide through
January 2021 [2]. Despite vast ongoing efforts to identify
potential treatments for patients with acute COVID-19,
few therapies have demonstrated benefit, and these
drugs appear to only be effective for certain subgroups
of patients with COVID-19 [3, 4]. The recent approval
of two vaccines offers promise for preventing new infections in the future [5, 6]. However, logistics of manufacturing and deploying the vaccine worldwide appear
challenging, especially in resource-poor and developing
nations [7–9]. Additionally, many people appear reluctant to receive SARS-CoV-2 vaccines even when they do
become widely available [10]. Furthermore, vaccines are
unlikely to completely eliminate COVID-19 in vaccinated populations [11–14]. Thus, COVID-19 may be a
major cause of morbidity and mortality for the foreseeable future and effective therapies to treat patients
moderately and severely ill with COVID-19 are urgently
needed.
Rationale for convalescent plasma as a therapy for
COVID-19

The use of convalescent plasma as a therapy for acute
infections relies on the concept of transferring neutralizing antibodies from a person who recently recovered
from the disease and developed a robust pathogenspecific immune response to another person who is in
the early stages of the infection and has not fully developed his or her own immune response. This type of
therapy is often called passive immune therapy or passive antibody therapy.
Based on strong biological rationale, convalescent
plasma has been used for more than a century to treat
outbreaks of viral diseases, especially when therapeutic

options have been lacking [15, 16]. However, convalescent plasma therapy has rarely been evaluated by
rigorously designed randomized trials, resulting in little
empiric evidence to support its use. Argentine
hemorrhagic fever is the only viral illness for which
convalescent plasma was conclusively shown to be
efficacious [17].

Expanded access program and emergency use
authorization

Despite limited data on efficacy, hundreds of thousands
of patients have received COVID-19 convalescent
plasma outside of a clinical trial. The expanded access
program (EAP) in the US for COVID-19 convalescent
plasma was started in April 2020. More than 90,000 patients were treated in through this program, which was
primarily designed to provide access to convalescent
plasma early in the pandemic and only secondarily to
evaluate safety and effectiveness [18, 19]. Less than 1%
of treated patients experienced a transfusion reaction
[20]. Because the program did not include a control
group, efficacy was assessed by comparing clinical outcomes among patients who received convalescent
plasma with high, medium, and low levels of SARSCoV-2 antibodies, using the concept that better clinical
outcomes in patients who received plasma with higher
antibody levels would suggest efficacy [21]. Antibody
levels were retrospectively measured with the OrthoClinical Diagnostics VITROS IgG semiquantitative assay
and classified into the following three groups: (1) high
antibody level (signal-to-cutoff ratio > 18.45); (2) medium
antibody level (signal-to-cutoff ratio 4.62–18.45); and (3)
low antibody level (signal-to-cutoff < 4.62). Among 3082
patients who received a single unit of convalescent
plasma with measured antibody levels, and thus could
be assigned to a single category of antibody level, 30day mortality varied in a “dose-dependent” pattern by
antibody titer level: 22.3% mortality in the high titer
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group, 27.4% in the medium titer group, and 29.6% in
the low titer group [19].
Citing results of the EAP, along with a small trial from
China [22] and a trial from the Netherlands [23] that
halted early, the Food and Drug Administration (FDA)
issued an emergency use authorization (EUA) on August
23, 2020, for COVID-19 convalescent plasma to treat
hospitalized COVID-19 patients [20]. At that time, the
FDA concluded that existing evidence suggested that
COVID-19 convalescent plasma with high antibody titer
may be beneficial but emphasized that additional highquality randomized clinical trials were important to
more definitively understand the efficacy of COVID-19
convalescent plasma.

convalescent plasma treatment may be efficacious for
early, mild disease [26].
Results from these trials published after the FDA
emergency use authorization were unknown at the time
that PassITON was designed. However, it is noteworthy
that unlike PassITON, many prior studies of COVID-19
convalescent plasma either did not quantify SARS-CoV2 antibody titers or screened convalescent plasma units
for SARS-CoV-2 antibodies with binding assays without
testing for neutralization. Among patients with high detectable levels of SARS-CoV-2 antibodies, only approximately 40–50% appear to have neutralizing function
[28]. Therefore, many prior COVID-19 convalescent
plasma studies likely included plasma units without neutralizing function.

Clinical trials of COVID-19 convalescent plasma

Goal of this trial

COVID-19 convalescent plasma trials published after
the announcement of the EUA include the PLACID [24]
and PlasmAR [25] trials conducted among hospitalized
adults in India and Argentina, respectively, and another
trial of older outpatient adults in Argentina [26].
Neither PLACID nor PlasmAR suggested efficacy for
COVID-19 convalescent plasma. PLACID enrolled 464
patients randomized to convalescent plasma administered in two 200 mL doses versus usual care in an unblinded fashion. Neutralizing capacity of the plasma was
measured retrospectively and less than one-third of the
units transfused in the study possessed neutralizing antibody titers ≥ 1:80 by a microneutralization assay. The
randomized, blinded, placebo-controlled PlasmAR trial
enrolled 335 patients in a 2:1 convalescent plasma-toplacebo ratio. Convalescent plasma units were chosen
for transfusion if they were found to have SARS-CoV-2
IgG titers 1:800 by the COVIDAR assay. Retrospective
analysis of neutralizing titers in 125 (56%) of the infused
doses showed an 80% inhibitory concentration median
titer of 1:300. Treatment with convalescent plasma in
this trial did not significantly improve clinical status at
30 days as measured on a six-level ordinal scale. A subsequent meta-analysis of available observational studies
and clinical trials involving hospitalized patients suggested potential efficacy for COVID-19 convalescent
plasma [27].
Libster et al. conducted a randomized trial of 160 outpatients who were ≥ 65 years old with mild COVID-19
and symptoms < 72 h [26]. Participants were randomized
in a 1:1 ratio to “high titer” COVID-19 convalescent
plasma (IgG titer greater than 1:1000 against the spike
protein) or placebo. Progression to severe respiratory
disease, defined as a respiratory rate ≥ 30 breaths/min or
oxygen saturation < 93% while breathing room air, occurred in fewer patients randomized to convalescent
plasma (16%) than placebo (31%), suggesting COVID-19

Rigorous clinical trials evaluating the efficacy COVID-19
convalescent plasma with neutralizing activity are
needed to guide clinical practice regarding the use of
convalescent plasma during the current pandemic and
also to understand if developing a scalable infrastructure
for collecting, testing, and disseminating convalescent
plasma is an important investment to prepare for future
outbreaks of novel viruses. Convalescent plasma could
be an immediately available therapy in the early stages of
future viral pandemics in resource-rich and resourcelimited nations. Understanding the efficacy of convalescent plasma in the current COVID-19 pandemic could
help inform decisions on pursuing convalescent plasma
as a therapy for future pandemics.
This study—the Passive Immunity Trial for Our Nation (PassITON)—was designed to provide the highest
quality evidence on the efficacy of COVID-19 convalescent plasma as a therapy for adults hospitalized with
moderate-to-severe acute COVID-19.

Methods
Design and oversight

PassITON is a multicenter, blinded, placebo-controlled,
parallel group, randomized clinical trial evaluating the
efficacy of COVID-19 convalescent plasma with neutralizing antibodies for the treatment of adults hospitalized
with acute COVID-19. The trial is funded by the National Center for Advancing Translational Sciences
(NCATS—https://ncats.nih.gov/contact) of the National
Institutes of Health (NIH). NCATS played no part in
study design, collection, management, analysis, or interpretation of data, writing of the report, or the decision
to submit the report for publication. The trial is conducted at hospitals across the USA including both academic medical centers (many of which are part of the
NCATS Clinical and Translational Science Awards
(CTSA) Program) and regional/city hospitals. All US
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hospitals with sufficient research enabling infrastructure
are eligible to be a site in PassITON regardless of size or
location.
Vanderbilt University Medical Center serves as the
clinical coordinating center, data coordinating center,
and single institutional review board (IRB number:
201672). The PassITON study team is located at Vanderbilt University Medical Center and is responsible for
direct trial oversight via twice weekly meetings. This
team is comprised of the study principal investigators,
statisticians, project managers, operations managers,
content experts, and study coordinators. Protocolrelated changes, inclusion of ancillary studies, and other
high-level decision-making are conducted by the PassITON Steering Committee (all site principal investigators) at biweekly meetings.
Treatment with convalescent plasma in this trial is
through an investigational new drug (IND number
21080) application submitted to the FDA. The trial was
registered with ClinicalTrials.gov (NCT04362176) prior
to enrollment of the first participant on April 28, 2020.
Progress and safety of the trial is monitored by an independent Data and Safety Monitoring Board (DSMB).
Prior to initiation of study procedures, informed consent is obtained by a trained study coordinator or investigator from each patient or a legally authorized
surrogate decision-maker if the patient is unable to
make medical decisions. On the consent form, participants are asked if they agree to use of their data should
they choose to withdraw from the trial. Participants are
also asked for permission for the research team to share
relevant data with people from the sites taking part in
the research or from regulatory authorities, where relevant. This trial does not involve collecting biological
specimens for storage. Consent is obtained electronically
or on paper. There is no anticipated harm from participating in this trial or provision for harm-related
compensation.
The trial protocol was developed according to the
SPIRIT guidelines (Supplementary Materials, Supplemental Figure 1). Protocol modifications and changes to
study-related procedures are communicated to the study
team and investigators through twice weekly internal coordinating center team meetings, weekly PassITON
newsletters disseminated both internally and externally
to site staff and investigators, and biweekly Steering
Committee meetings attended by site investigators and
coordinators.
Collection of convalescent plasma

The plasma collection component of PassITON was developed to optimize the efficient procurement of
COVID-19 convalescent plasma with high levels of neutralizing antibodies. Convalescent plasma is collected
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from adults mainly residing around Nashville, Tennessee
who have recovered from COVID-19 in a collaborative
effort between Vanderbilt University Medical Center and
Blood Assurance, a nonprofit regional blood center
based in Chattanooga, Tennessee. Patients with
laboratory-confirmed SARS-CoV-2 infection with selfreported symptom severity of at least 3 on a 10-point
scale (range: 1, “I feel healthy” to 10, “I was/should have
been in the Intensive Care Unit (ICU)”) are eligible for
plasma donation. Recovered patients are identified
through several methods including Vanderbilt hospital
records, mass email through the Vanderbilt employee
list, public advertising in the community, ResearchMatch [29, 30], and self-identification. Patients are able
to donate plasma if they have recovered from acute
COVID-19, defined as either: (1) being symptom-free for
14 days and having at least one negative COVID-19 test
by RT-PCR, or (2) being symptom-free for at least 28
days. All donors must also meet FDA requirements for
blood product donation [31]. Donors sign an IRBapproved informed consent for participation prior to
phlebotomy. Donors have a blood sample collected for
characterization of circulating SARS-CoV-2 antibodies
(see next section) and then immediately have blood collected for plasma donation units (Fig. 1).
Plasma collection is performed via apheresis using the
Fresenius-Kabi ALYX instrument, which allows for the
collection of up to four units per donation. Patients are
invited to return for additional donations if antibody
testing demonstrates high antibody levels (≥ 20,000 EU/
mL by anti-Receptor Binding Domain (RBD) IgG binding assay) and neutralizing activity. Through an FDA
variance obtained by Blood Assurance, participants are
allowed to donate as frequently as every 7 days for 4
visits before evaluation of total protein and serum albumin to confirm safety of continued donations.
Selection of convalescent plasma for the trial

Serum is obtained from convalescent plasma donors at
the time of donation. These serum samples are used for
antibody quantification. Donor sera are initially screened
by the Abbott™ ARCHITECT™ IgG qualitative platform
for the presence of detectable antibody against SARSCoV-2. Samples positive in the Abbott assay are then
assessed by the quantification of binding IgG against the
RBD of SARS-CoV-2 using a liquid bead-array assay as
previously described [32]. Briefly, recombinant RBD is
conjugated to Luminex MagPlex microspheres and incubated in 96 well plates with serially diluted serum
samples and a cross-reactive SARS-CoV-2 monoclonal
antibody as a standard. Serum antibodies bound to
SARS-CoV-2 SRBD are detected by R-Phycoerythrin conjugated F(ab’)2 fragment goat anti-human IgG Fc
gamma conjugate (Jackson ImmunoResearch). Data are
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Fig. 1 Donor selection pipeline for obtaining COVID-19 convalescent plasma for PassITON. Images obtained from flaticon.com

acquired using a Luminex MagPix Instrument at 100
beads per well, with Xponent software version 4.3.
Through September 30, 2020, donor samples were
screened exclusively using the Abbott™ ARCHITECT™
platform and the RBD Luminex assay (Fig. 2). Units with
a minimum threshold mean fluorescence intensity (MFI)
of 8000 were deemed eligible for transfusion. This cutoff
was determined by screening a subset of samples for
neutralization using a traditional live-virus plaquereduction neutralization titer (PRNT) assay. Two- or
four-fold serial dilutions of sera in gelatin saline were incubated for 20 min at 37 °C with an average of 130
plaque-forming units of SARS-CoV-2 isolate SARS-CoV2/human/USA/USA-WA1/2020 (GenBank: MN985325.1)
in 200 μl gelatin saline, and 100 μl of virus-serum mixtures
were applied to each of two Vero E6 cell monolayers in
10 cm2 dishes. Following virus adsorption for 30 min at
37 °C, monolayers were overlaid with 1% agar in cell

culture medium and incubated for 3 days at 37 °C, at
which time plaques were enumerated by direct visual inspection. Percent neutralization was defined as fractional
plaque reduction in the presence of serum relative to
untreated (saline only) virus. Neutralization titers were interpolated from dose-response curves fit to results of duplicate neutralization testing using five-parameter logistic
regression modeling implemented in GraphPad Prism.
Beginning October 1, 2020, an additional screening
step was introduced to confirm the presence of SARSCoV-2 neutralizing antibodies. In the modified format,
donor samples still undergo screening via the Abbott™
ARCHITECT™ platform and the RBD Luminex assay.
Samples are excluded if they are found to be negative via
the Abbott™ ARCHITECT™ of having an MFI < 8000 as
determined by the RBD Luminex assay. Samples with an
antibody level (MFI) above 8000 are then screened for
the ability to neutralize virus by functional assessment
with a high-throughput assay platform using real-time,
quantitative cellular analysis on the xCELLigence platform (Agilent Technologies, Santa Clara, CA), using
chimeric vesicular stomatitis virus (VSV) expressing intact SARS-CoV-2 spike protein, as previously described
[33, 34]. Samples with a 50% neutralization titer > 1:50
are selected for transfusion in the trial (Fig. 2).
Antibody testing is completed at Vanderbilt University
Medical Center. Convalescent plasma units are stored at
Blood Assurance and shipped to enrolling sites in the
trial as needed. Between April 22, 2020, and January 29,
2021, 429 donors provided over 1200 convalescent
plasma units, with plans to continue donations for the
duration of the trial. Approximately 25% of the plasma
donations in this program have passed the antibody
screening steps and been selected for use in the trial.
Trial participants

Fig. 2 COVID-19 convalescent plasma selection for PassITON. Each
convalescent plasma unit used in the trial is selected based on
quantitative anti-SARS-CoV-2 antibody levels and neutralization

Patients eligible for enrollment in the trial include adults
hospitalized with laboratory-confirmed SARS-CoV-2 infection and respiratory symptoms consistent with
COVID-19 for fewer than 14 days. Patients hospitalized
in either ICU or less intensive areas are eligible. Major
exclusion criteria include planned hospital discharge
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within 24 h and prior receipt of COVID-19 convalescent
plasma or another passive immunity therapy in the prior
30 days. Participants identified as eligible for the study
are approached for consent by a study coordinator or investigator. Recruitment materials include a flyer, fact
sheet, and website (https://passitonstudy.org) which contains informative videos from physicians, researchers,
and past participants. All recruitment materials have
been translated to Spanish, Arabic, and simple Chinese.
To further support recruitment, there are fully translated
consent forms in > 20 languages. PassITON recruitment
will continue at all sites until the accrual goal of 1000
participants is met.
Randomization and treatment groups

Enrolled patients are randomized in a 1:1 ratio to
COVID-19
convalescent
plasma
or
placebo.
Randomization is completed by a centralized web-based
platform and stratified by site, sex, and age. Patients randomized to convalescent plasma receive a single dose of
1 unit (200–399 mL) of COVID-19 convalescent plasma
infused intravenously. Patients randomized to placebo
receive a single 250 mL dose of lactated Ringer’s solution
containing multivitamin infused intravenously. Multivitamins are added to the placebo solution to produce a
yellow color that matches the color of plasma.
The study infusion (convalescent plasma or placebo) is
administered as soon as possible and within 24 h after
randomization. Infusion of study treatment is halted if
the study participant exhibits any symptoms of transfusion reaction or anaphylaxis. Patients are observed for 6
h after initiation of the study infusion for signs and
symptoms of a transfusion reaction. Use of open-label
convalescent plasma is strongly discouraged for the first
14 days following the study infusion. Other aspects of
clinical management are performed at the discretion of
the treating clinicians without influence from the study
protocol.
Blinding

In order to safely administer a blood product in the trial
and also maintain blinding of the patient, investigators,
and outcome assessors, the trial uses both blinded and
unblinded study personnel. At each site, the lead investigator remains blinded to study group assignment. An
unblinded study member randomizes patients, receives
the treatment assignment, and then orders convalescent
plasma or the placebo solution based on the randomized
treatment assignment. The study treatment is delivered
to the patient’s bedside, where an unblinded clinical
nurse places the study treatment in a blinding bag before
entering the patient’s room. The unblinded clinical nurse
then infuses the treatment. Clinical monitoring, including vital sign assessment, is completed based on local
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practices for monitoring an infusion of plasma regardless
of randomized group. The clinical providers (e.g., physicians), patient, and outcome assessors remain blinded to
study group assignment. Participant unblinding is performed by unblinded site coordinators and is permitted
only after the study follow-up period is complete and if
unblinding will directly impact the individual’s course of
clinical care (e.g., timing of COVID-19 vaccination).
Outcomes

The primary outcome is the patient’s clinical status on a
7-category ordinal scale (the COVID-19 7-point Ordinal
Clinical Progression Outcomes Scale) 14 days after the
study infusion. The 7 categories are (1) not hospitalized
with resumption of normal activities; (2) not hospitalized, but unable to resume normal activities; (3) hospitalized, not on supplemental oxygen; (4) hospitalized,
and on supplemental oxygen; (5) hospitalized, on nasal
high-flow oxygen therapy, noninvasive mechanical ventilation, or both; (6) hospitalized, on ECMO, invasive
mechanical ventilation, or both; and (7) death. While the
patient is hospitalized, the ordinal scale category is identified by direct patient observation and medical record
review. After hospital discharge, patients are contacted
by telephone to distinguish between category 1 and category 2. This scale was developed by the World Health
Organization [35] (WHO) early in the pandemic as a
patient-centered clinical outcome for COVID-19 and
has been successfully used in multiple clinical trials [3,
36, 37]. Secondary and safety outcomes are shown in
Table 1.
Data collection, monitoring, and dissemination

Randomization and data collection are being conducted
through Research Electronic Data Capture (REDCap).
The randomization module in REDCap allows the statistician to load a randomization table that will allow the
study personnel to click a “randomize” button. REDCap
is a secure, web-based application designed to support
data capture for research studies, providing (1) an intuitive interface for validated data entry; (2) audit trails for
tracking data manipulation and export procedures; (3)
automated export procedures for seamless data downloads to common statistical packages; and (4) procedures
for importing data from external sources.
Data quality is reviewed remotely using front-end
range and logic checks at the time of data entry and
back-end monitoring of data using application programming interface tools connecting the online database to
statistical software to generate data reports. Patient records and case report forms are also be reviewed to
evaluate the accuracy and completeness of the data entered into the database and monitored for protocol compliance per the study monitoring plan.
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Table 1 Trial outcomes. Definitions for all outcome are provided in the statistical analysis plan available in the Supplementary
Materials
Outcomes

Variable type

Approach to analysis

COVID-19 7-point Ordinal Clinical Progression Outcomes Scale
14 days after randomization (assessed on study day 15)

Ordinal

Cumulative probability model with logit link

All-location, all-cause 14-day mortality (assessed on study day 15)

Binary

Logistic regression

All-location, all-cause 28-day mortality (assessed on study day 29)

Binary

Logistic regression

Survival through 28 days

Time-to-event

Proportional hazards regression

Time to hospital discharge through 28 days

Time-to-event

Multistate model with death as a competing risk

Time to recovery

Time-to-event

Cumulative probability model with logit link

COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on
study days 3, 8 and 29

Ordinal

Cumulative probability model with logit link

Oxygen-free days through day 28

Ordinal

Cumulative probability model with logit link

Ventilator-free days through day 28

Ordinal

Cumulative probability model with logit link

Vasopressor-free days through day 28

Ordinal

Cumulative probability model with logit link

Efficacy outcomes

ICU-free days through day 28

Ordinal

Cumulative probability model with logit link

Hospital-free days through day 28

Ordinal

Cumulative probability model with logit link

Receipt of renal replacement therapy

Binary

Risk difference

Venous thromboembolic disease (deep vein thrombosis or pulmonary
embolism)

Binary

Risk difference

Cardiovascular event (myocardial infarction or ischemic stroke)

Binary

Risk difference

Safety outcomes

Transfusion reaction

Binary

Risk difference

Transfusion related acute lung injury (TRALI)

Binary

Risk difference

Transfusion associated circulatory overload (TACO)

Binary

Risk difference

Transfusion-related infection

Binary

Risk difference

The data generated from the PassITON trial will be
released via publication. It will also be shared at seminars, symposiums, and meeting presentations as well as
deposited in appropriate databases. Before releasing any
of this information, the raw data will be stripped of identifiers in order to remain compliant with HIPAA and
other governing agencies’ guidelines. The datasets analyzed during the current study are available from the
corresponding author upon reasonable request.
Statistical analysis

In this section, we describe key statistical features of the
trial. The full statistical analysis plan for the trial is included in the Supplemental Materials.
General approach to analysis

The statistical design for this trial was informed by the
need to learn as rapidly as possible from the data during
the pandemic while simultaneously managing the risk of
drawing erroneous conclusions. Rapid decision-making
to maximally inform clinical care during an ongoing
pandemic requires flexibility for the DSMB to perform
unplanned evaluations of the data and potentially

decrease or increase the sample size of the trial. This requires a trial framework that does not demand that all
possible interim analyses are prespecified, as is required
of approaches using p values. Two closely related approaches which offer the needed flexibility are the Likelihood and Bayesian frameworks. We selected the
Likelihood framework for this trial. The Likelihood approach has been successfully implemented in clinical trials with continuous monitoring or sequential methods
[38, 39], because it retains its meaning and reliability regardless of the number of interim analyses or outcomes
under consideration [40, 41].
Decision-making using the likelihood approach in a
clinical trial center on three quantities: the point estimate of the treatment effect (an odds ratio, for example),
a corresponding interval estimate, and a single number
summary that measures the relative evidence for one hypothesis (for example, convalescent plasma being superior to placebo) compared to another hypothesis (for
example, convalescent plasma not being superior to placebo). These three quantities are similar to the point estimate, 95% confidence interval, and p value that are
generated in frequentist analyses. In fact, point estimates
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using the likelihood and frequentist approaches are often
identical, and the interval estimates are often very similar to 95% confidence intervals. The likelihood ratio (LR)
and the p value, however, are distinct measures of evidence. The LR is a ratio: the density of the trial data if
the treatment is effective (alternative hypothesis) divided
by the density of the trial data if the treatment is not effective (null hypothesis). A LR of 1 indicates the data are
neutral; neither the alternative hypothesis nor null hypothesis is supported more strongly than the other. A
large LR is evidence in support of the treatment being
effective. An LR less than one is evidence that the treatment is harmful. In this trial, a LR ≥ 7 in favor of the
intervention group is considered sufficient evidence to
assert that the treatment is beneficial.
The likelihood approach is different than using pvalues as the level of evidence because the p-value compares what actually happened in the trial to what might
have happened if the trial were repeated infinitely and
the null hypothesis was true. Because it is impossible to
compute what might have happened if the rules for
decision-making are not fully predefined, using a p-value
for decision making is not well suited for a trial like this
in which pandemic circumstances prompt urgent design changes. The LR approach, on the other hand, is
based on a relative likelihood of observed outcomes
under two competing models at the same point in
time, making it especially appropriate for settings
where pre-specification of the timing or frequency of
sequential analyses is not possible.
Interim analyses

The anticipated sample size is 1000 enrolled patients.
The trial includes three planned interim analyses, to be
conducted after primary outcome data collection is completed for 150, 450, and 750 study participants. Additional interim analyses may be called at any time by the
DSMB based on changes in the pandemic and/or emerging data on COVID-19 convalescent plasma. Adverse
events, safety outcomes, protocol deviations, and the
primary endpoint are presented to the DSMB at each interim analysis. Additionally, as a safety evaluation, the
difference in mortality risk between groups is calculated,
and the one-sided hypothesis that mortality risk in the
intervention arm exceeds the mortality risk in placebo
will be compared to the null hypothesis of equal mortality risk. The trial will be stopped for safety if the likelihood ratio for mortality exceeds any of the following
thresholds, suggesting increased mortality with convalescent plasma: first interim analysis, LR 6.3 (which corresponds to a p value of approximately 0.0275); second
interim analysis, LR 4.0 (which corresponds to a p value
of approximately 0.0479); and third interim analysis, LR
3.3 (which corresponds to a p value of approximately
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0.0612). These thresholds result in a 0.1 trial-wise risk of
stopping the trial early for mortality if mortality were
truly equivalent in the intervention and control groups.
There are no pre-specified stopping rules for efficacy.
Primary analysis of the primary outcome

The primary analysis will be intention-to-treat, with each
randomized patient analyzed according to the randomized treatment assignment (convalescent plasma vs. placebo) regardless of the treatment received. The main
result will be an estimate of the treatment effect odds ratio, its likelihood ratio when compared to the null, and
the corresponding 1/7 likelihood support interval, all of
which will be estimated from a cumulative probability
ordinal regression model (CPM) with logit link. The
marginal likelihood function for the treatment effect parameter will be the asymptotic regression coefficient distribution; specifically, it will be the normal distribution
density function with mean and standard deviation equal
to the regression estimates. An odds ratio < 1.0 indicates
more favorable results on the COVID 7-point Ordinal
Clinical Progression Outcomes Scale in the intervention
group compared with the control group. Likelihood ratios more extreme than 7 will be interpreted as sufficient
evidence to assert efficacy.
The primary model will adjust for the following six
baseline characteristics: age (2 parameters, restricted
cubic spline); sex (1 parameter); baseline SOFA score (1
parameter, linear term); baseline COVID-19 7-point
Ordinal Clinical Progression Outcomes Scale score (possible range: 3–6) (2 parameters, quadratic); time from
symptom onset to randomization in days (2 parameter,
non-linear term); and a site indicator variable (as a random effect).
Additional analyses of the primary outcome

A per-protocol analysis of the primary outcome will be
performed in which randomized patients who did not
receive any volume of the study treatment are excluded.
The impact of convalescent plasma quality, as measured by antibody quantification and neutralization, on
the primary outcome will be estimated with two ordinal
regression models. In the first, the model will include
the same covariates listed for the primary analysis with
the addition of a measure of donor plasma binding level
(value in MFI obtained using the RBD Luminex-based
assay [32]). In the second model, a measure of donor
plasma neutralization (NT50 value obtained using the
VSV-SARS-CoV-2 chimeric virus neutralization assay
[33, 34]) will be used. Both of these variables of convalescent plasma quality will be included in the models as
a restricted cubic spline with three knots to capture potential non-linear associations with the outcome. For observations in the control arm, binding and neutralization
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values will be set to zero. Studies to evaluate alternative
measures of convalescent plasma quality are ongoing
and, dependent on the results of those analyses, a different measure of quality may be selected.
The degree to which pre-specified baseline variables
modify the treatment effect will be examined with tests
of statistical interaction in a cumulative probability ordinal regression model. Independent variables will include study group assignment, the potential effect
modifier of interest, the interaction between the two,
and the same pre-specified covariates used in the primary model. Presence of effect modification will be
assessed by reference to the LR for the interaction term,
with values greater than 6 considered to suggest a potential interaction and values greater than 7 considered to
confirm an interaction. The baseline variables that will
be evaluated for effect modification include: baseline recipient (trial participant) serum antibody quantification;
baseline COVID-19 7-point Ordinal Clinical Progression
Outcomes Scale score; baseline SOFA score; location at
time of enrollment (ICU/ward); age; race/ethnicity; duration of COVID-19 symptoms prior to randomization
(days in linear form); and mechanical ventilation status
at baseline.
Sample size and power

The operating characteristics of the trial design were estimated by simulating study data to reflect different
treatment effect sizes. Simulations for study power were
performed on Amazon Elastic Compute Cloud servers
using R version 4.0.2 [42] with the following packages:
ordinal [43], magrittr [44], and doRedis [45]. The simulated study dataset was evaluated according to the stopping rule and analysis plan described above. For each
effect size, 1000 simulated datasets were analyzed. A
type I error occurred if the study asserted efficacy when
in fact there was no treatment effect. The type I error
rate was calculated as the proportion of simulated studies with no treatment effect in which the error occurred.
A type II error occurred if the study failed to assert efficacy when there was a beneficial treatment effect. For
each treatment effect, power was calculated as the proportion of simulated studies that did not result in a type
II error.
The study endpoint for control subjects was simulated
to match the outcomes in the control arm of a recent
clinical trial [46]. In each simulation setting, the distribution for the treatment arm was calculated by adjusting
the control arm outcome distribution according to the
setting-specific treatment effect size and data generation
model.
These simulations demonstrated that enrollment of
1000 patients (500 patients in the intervention group
and 500 patients in the control group) would provide
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80% power to detect an adjusted odds ratio of ≤ 0.73
(Fig. 3). Some trials orient the ordinal outcomes scale in
the reverse direction, with an odds ratio greater than 1.0
indicating benefit from the intervention [3, 36]. With reversal of the ordinal outcomes scale, enrollment of 1000
patients would provide 80% power to detect an adjusted
odds ratio ≥ 1.37. The simulations also demonstrated
that the type I error rate was below 0.05.
Analysis of secondary and safety outcomes

Secondary efficacy outcomes will be assessed by
intention-to-treat analyses using the same covariables as
the primary model for the primary outcome. Safety outcomes will be analyzed in the safety population, classified based on receipt of convalescent plasma from the
trial vs. those who received placebo from the trial regardless of randomized assignment, without covariable
adjustment. Adjustments will not be made for multiple
comparisons.

Discussion
PassITON is an ongoing blinded, placebo-controlled
randomized trial evaluating the efficacy of COVID-19
convalescent plasma for the treatment of adults hospitalized with moderate-to-severe acute COVID-19. The first
patient was enrolled on April 28, 2020, and trial completion is anticipated in 2021.
COVID-19 convalescent plasma has been administered
to hundreds of thousands of patients in the USA, initially under an EAP [47] and now under EUA [20].
While data from these programs support the safety of

Fig. 3 Power of the trial to detect different effect sizes (treatment
effect odds ratios) in the primary outcome with enrollment of 1000
participants. The primary outcome is the COVID-19 7-point Ordinal
Clinical Progression Scale, analyzed with a cumulative probability
model. An odds ratio < 1.0 indicates more favorable clinical
outcomes on the scale in the convalescent plasma group than the
placebo group. With enrollment of 1000 participants, the trial has
power to detect on odds ratio ≤ 0.73
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convalescent plasma, evidence of efficacy is lacking. PassITON is designed to provide rigorous efficacy data. As
such, key design features include meticulous selection of
convalescent plasma with high levels of anti-SARS-CoV2 antibodies with neutralizing activity; enrollment of a
geographically diverse patient population in hospitals
across the USA; patient-level randomization to COVID19 convalescent plasma or matching placebo; blinding of
participants, investigators and outcome assessors to
treatment assignment; and systematic collection of
patient-centered outcomes for 4 weeks following
infusion of the study treatment. These characteristics
distinguish PassITON from many other COVID-19 convalescent plasma trials which have either reported null
findings (PLACID [24], PlasmAR [25]) or recently
stopped for futility [48, 49].
In addition, the rigorous plasma donation and screening program required in PassITON to ensure the use of
COVID-19 convalescent plasma with potent neutralizing
antibodies has demonstrated important challenges that
would need to be overcome to develop a scalable pipeline for supplying neutralizing COVID-19 convalescent
plasma if it is found to be an effective therapy. With only
approximately 25% of units donated from patients who
have recovered from COVID-19 having neutralizing activity, stringent donor screening and antibody quantification steps would need to be implemented to ensure the
use of effective convalescent plasma.
PassITON evaluates the efficacy of COVID-19 convalescent plasma among hospitalized patients, which
is the same population described in the FDA EUA
[20]. The efficacy of COVID-19 convalescent plasma
among patients with less severe disease and/or who
are earlier in their disease course is being evaluated
in other trials [50, 51].
Convalescent plasma had been used as a therapy for
severe viral illnesses for over a century and in hundreds
of thousands of COVID-19 patients during the past year.
Despite this enthusiastic use of convalescent plasma, its
clinical efficacy remains unclear. Effectively managing
COVID-19 patients in the current pandemic and developing a robust infrastructure to respond to future viral
pandemics requires evidence-based answers to longstanding questions about the efficacy of convalescent
plasma. PassITON will advance our understanding of
convalescent plasma, and combined with other work,
help inform treatment options for COVID-19 and future
pandemics.

Trial status
The PassITON trial launched in April 2020 as a singlecenter study at Vanderbilt University Medical Center
with funding from the Dolly Parton COVID-19 Research
Fund. The trial expanded to a multicenter study in
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August 2020 with funding from the NCATS of the National Institutes of Health (NIH). Prior to expansion to
the multicenter format, 66 participants had been enrolled at Vanderbilt. Interim analyses conducted by the
independent DSMB after enrollment and completion of
the primary outcome by 151 and 469 study participants
resulted in recommendations to continue the study
without modification. PassITON is currently enrolling
under protocol version 5.0 dated September 15, 2020.
Trial completion is expected by May 31, 2021.
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